{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-011842","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2025-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.230574+00:00","generated_at":"2026-05-20T22:20:35.906886+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"INVO Fertility Q1 2025 revenue up 4% but net loss widens to $17.4M on $14.6M impairment","bullets":["Revenue $1.64M, +4% YoY; clinic revenue from consolidated centers +5% to $1.62M.","Net loss of $17.4M vs $1.6M; includes $14.6M non-cash impairment on NAYA Therapeutics assets.","Adjusted EBITDA loss widened to $(606,551) from $(427,467) in prior year.","Company refocuses on fertility after April 2025 decision to divest majority stake in NAYA TX.","CEO cites supportive policy shifts and aims for cash flow break-even through clinic expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-011842","json":"https://secwatch.observer/filing/0001641172-25-011842.json","markdown":"https://secwatch.observer/filing/0001641172-25-011842.md","text":"https://secwatch.observer/filing/0001641172-25-011842.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225011842/0001641172-25-011842-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225011842/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T22:20:35.906886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}